Terms: = Prostate cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Staging
18 results:
1. ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical prostatectomy for High-risk prostate cancer.
Devos G; Tosco L; Baldewijns M; Gevaert T; Goffin K; Petit V; Mai C; Laenen A; Raskin Y; Van Haute C; Goeman L; De Meerleer G; Berghen C; Devlies W; Claessens F; Van Poppel H; Everaerts W; Joniau S
Eur Urol; 2023 Jun; 83(6):508-518. PubMed ID: 36167599
[TBL] [Abstract] [Full Text] [Related]
2. A circadian rhythm-related gene signature for predicting relapse risk and immunotherapeutic effect in prostate adenocarcinoma.
Liu J; Tan Z; Yang S; Song X; Li W
Aging (Albany NY); 2022 Sep; 14(17):7170-7185. PubMed ID: 36103249
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic Features of Biochemical Recurrence of prostate cancer Following Radical prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens.
Harmon SA; Gesztes W; Young D; Mehralivand S; McKinney Y; Sanford T; Sackett J; Cullen J; Rosner IL; Srivastava S; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Dobi A; Sesterhenn IA; Turkbey B
Radiology; 2021 Jun; 299(3):613-623. PubMed ID: 33847515
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive analysis in mucin-producing urothelial-type adenocarcinoma of the prostate: case study with literature review.
Moe K; Maa HC; Pei D; Liang YJ; Chen YL
Pol J Pathol; 2020; 71(3):244-253. PubMed ID: 33112115
[TBL] [Abstract] [Full Text] [Related]
5. Apoptotic and predictive factors by Bax, Caspases 3/9, Bcl-2, p53 and Ki-67 in prostate cancer after 12 Gy single-dose.
Pisani C; Ramella M; Boldorini R; Loi G; Billia M; Boccafoschi F; Volpe A; Krengli M
Sci Rep; 2020 Apr; 10(1):7050. PubMed ID: 32341393
[TBL] [Abstract] [Full Text] [Related]
6. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
Ishkanian AS; Zafarana G; Thoms J; Bristow RG
Acta Oncol; 2010 Oct; 49(7):888-94. PubMed ID: 20590366
[TBL] [Abstract] [Full Text] [Related]
7. p53 immunochemistry is an independent prognostic marker for outcome in conservatively treated prostate cancer.
Kudahetti S; Fisher G; Ambroisine L; Foster C; Reuter V; Eastham J; Møller H; Kattan MW; Cooper CS; Scardino P; Cuzick J; Berney DM
BJU Int; 2009 Jul; 104(1):20-4. PubMed ID: 19239456
[TBL] [Abstract] [Full Text] [Related]
8. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy.
Revelos K; Petraki C; Gregorakis A; Scorilas A; Papanastasiou P; Koutsilieris M
Anticancer Res; 2005; 25(4):3123-33. PubMed ID: 16080576
[TBL] [Abstract] [Full Text] [Related]
9. Prostatic ductal adenocarcinoma showing Bcl-2 expression.
Tulunay O; Orhan D; Baltaci S; Gögüş C; Müftüoglu YZ
Int J Urol; 2004 Sep; 11(9):805-8. PubMed ID: 15379952
[TBL] [Abstract] [Full Text] [Related]
10. p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer.
Wu HC; Chang CH; Chen HY; Tsai FJ; Tsai JJ; Chen WC
Urol Int; 2004; 73(1):41-6. PubMed ID: 15263792
[TBL] [Abstract] [Full Text] [Related]
11. Molecular markers in prostate cancer: the role in preoperative staging.
Moul JW; Merseburger AS; Srivastava S
Clin Prostate Cancer; 2002 Jun; 1(1):42-50. PubMed ID: 15046712
[TBL] [Abstract] [Full Text] [Related]
12. [Expressions of apoptosis-associated proteins in prostate carcinoma and their clinicopathological significance].
Zhang X; Li F; Jiang Y
Hua Xi Yi Ke Da Xue Xue Bao; 2000 Jun; 31(2):193-6. PubMed ID: 12515134
[TBL] [Abstract] [Full Text] [Related]
13. The role of imaging studies and molecular markers for selecting candidates for radical prostatectomy.
Moul JW; Kane CJ; Malkowicz SB
Urol Clin North Am; 2001 Aug; 28(3):459-72. PubMed ID: 11590806
[TBL] [Abstract] [Full Text] [Related]
14. Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging.
Kelavkar UP; Cohen C; Kamitani H; Eling TE; Badr KF
Carcinogenesis; 2000 Oct; 21(10):1777-87. PubMed ID: 11023533
[TBL] [Abstract] [Full Text] [Related]
15. Prediction of biochemical relapse for stage pT3 prostate cancer following radical prostatectomy.
Wu TT; Wang JS; Lu CM; Lee YH; Huang JK
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Feb; 63(2):124-30. PubMed ID: 10677923
[TBL] [Abstract] [Full Text] [Related]
16. Angiogenesis, p53, bcl-2 and Ki-67 in the progression of prostate cancer after radical prostatectomy.
Moul JW
Eur Urol; 1999; 35(5-6):399-407. PubMed ID: 10325496
[TBL] [Abstract] [Full Text] [Related]
17. Detection of minimal disease in patients with solid tumors.
Pantel K
J Hematother; 1996 Aug; 5(4):359-67. PubMed ID: 8877711
[TBL] [Abstract] [Full Text] [Related]
18. DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
Berner A; Waere H; Nesland JM; Paus E; Danielsen HE; Fosså SD
Br J Urol; 1995 Jan; 75(1):26-32. PubMed ID: 7531589
[TBL] [Abstract] [Full Text] [Related]
